Publication: Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy
Issued Date
2012-02-10
Resource Type
ISSN
03406245
Other identifier(s)
2-s2.0-84863012482
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Thrombosis and Haemostasis. Vol.107, No.2 (2012), 232-240
Suggested Citation
Benjamin D. Horne, Petra A. Lenzini, Mia Wadelius, Andrea L. Jorgensen, Stephen E. Kimmel, Paul M. Ridker, Niclas Eriksson, Jeffrey L. Anderson, Munir Pirmohamed, Nita A. Limdi, Robert C. Pendleton, Gwendolyn A. Mcmillin, James K. Burmester, Daniel Kurnik, C. Michael Stein, Michael D. Caldwell, Charles S. Eby, Anders Rane, Jonatan D. Lindh, Jae Gook Shin, Ho Sook Kim, Pantep Angchaisuksiri, Robert J. Glynn, Kathryn E. Kronquist, John F. Carlquist, Gloria R. Grice, Robert L. Barrack, Juan Li, Brian F. Gage Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thrombosis and Haemostasis. Vol.107, No.2 (2012), 232-240. doi:10.1160/TH11-06-0388 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/14952
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy
Author(s)
Benjamin D. Horne
Petra A. Lenzini
Mia Wadelius
Andrea L. Jorgensen
Stephen E. Kimmel
Paul M. Ridker
Niclas Eriksson
Jeffrey L. Anderson
Munir Pirmohamed
Nita A. Limdi
Robert C. Pendleton
Gwendolyn A. Mcmillin
James K. Burmester
Daniel Kurnik
C. Michael Stein
Michael D. Caldwell
Charles S. Eby
Anders Rane
Jonatan D. Lindh
Jae Gook Shin
Ho Sook Kim
Pantep Angchaisuksiri
Robert J. Glynn
Kathryn E. Kronquist
John F. Carlquist
Gloria R. Grice
Robert L. Barrack
Juan Li
Brian F. Gage
Petra A. Lenzini
Mia Wadelius
Andrea L. Jorgensen
Stephen E. Kimmel
Paul M. Ridker
Niclas Eriksson
Jeffrey L. Anderson
Munir Pirmohamed
Nita A. Limdi
Robert C. Pendleton
Gwendolyn A. Mcmillin
James K. Burmester
Daniel Kurnik
C. Michael Stein
Michael D. Caldwell
Charles S. Eby
Anders Rane
Jonatan D. Lindh
Jae Gook Shin
Ho Sook Kim
Pantep Angchaisuksiri
Robert J. Glynn
Kathryn E. Kronquist
John F. Carlquist
Gloria R. Grice
Robert L. Barrack
Juan Li
Brian F. Gage
Other Contributor(s)
Intermountain Medical Center
University of Utah
Washington University in St. Louis
Uppsala Universitet
University of Liverpool
University of Pennsylvania
Harvard Medical School
Brigham and Women's Hospital
Akademiska Sjukhuset
University of Alabama
ARUP Laboratories
Marshfield Clinic
Vanderbilt University
Karolinska Institutet
Inje University, College of Medicine
Mahidol University
Kaiser Permanente
St. Louis College of Pharmacy
University of Utah
Washington University in St. Louis
Uppsala Universitet
University of Liverpool
University of Pennsylvania
Harvard Medical School
Brigham and Women's Hospital
Akademiska Sjukhuset
University of Alabama
ARUP Laboratories
Marshfield Clinic
Vanderbilt University
Karolinska Institutet
Inje University, College of Medicine
Mahidol University
Kaiser Permanente
St. Louis College of Pharmacy
Abstract
By guiding initial warfarin dose, pharmacogenetic (PGx) algorithms may improve the safety of warfarin initiation. However, once international normalised ratio (INR) response is known, the contribution of PGx to dose refinements is uncertain. This study sought to develop and validate clinical and PGx dosing algorithms for warfarin dose refinement on days 6-11 after therapy initiation. An international sample of 2,022 patients at 13 medical centres on three continents provided clinical, INR, and genetic data at treatment days 6-11 to predict therapeutic warfarin dose. Independent derivation and retrospective validation samples were composed by randomly dividing the population (80%/20%). Prior warfarin doses were weighted by their expected effect on S-warfarin concentrations using an exponential-decay pharmacokinetic model. The INR divided by that "effective" dose constituted a treatment response index. Treatment response index, age, amiodarone, body surface area, warfarin indication, and target INR were associated with dose in the derivation sample. A clinical algorithm based on these factors was remarkably accurate: in the retrospective validation cohort its R 2 was 61.2% and median absolute error (MAE) was 5.0 mg/week. Accuracy and safety was confirmed in a prospective cohort (N=43). CYP2C9 variants and VKORC1-1639 G→A were significant dose predictors in both the derivation and validation samples. In the retrospective validation cohort, the PGx algorithm had: R 2 = 69.1% (p < 0.05 vs. clinical algorithm), MAE= 4.7 mg/week. In conclusion, a pharmacogenetic warfarin dose-refinement algorithm based on clinical, INR, and genetic factors can explain at least 69.1% of therapeutic warfarin dose variability after about one week of therapy. © Schattauer 2012.